Clinical Trials

420 enrolled

Lung Neoplasms, Small Cell Lung Carcinoma

NCT06828354 2026-04-20

A Study of SHR-A1811 in Subjects With Ovarian Cancer

300 enrolled

Ovarian Neoplasms

NCT06994195 2026-04-20

A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)

384 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT06459180 2026-04-17

TroFuse-020

686 enrolled

Uterine Cervical Neoplasms

NCT07213804 2026-04-17

FRAmework-01

1,080 enrolled

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms

NCT07214779 2026-04-16

MAESTRA 2

466 enrolled

Ovarian Neoplasms

NCT07418749 2026-04-06

A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer

398 enrolled

Uterine Cervical Neoplasms

NCT06930755 2026-03-31

Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer

Phase 1 Recruiting

24 enrolled

Ovarian Neoplasms

NCT06801834 2026-03-19

EVOKE-SCLC-04

695 enrolled

Extensive Stage Small Cell Lung Cancer (ES-SCLC)

NCT06203210 2026-03-02

IDeate-Lung02

540 enrolled

Small Cell Lung Carcinoma

NCT07218809 2026-01-16

TREVI-OC-01

1,100 enrolled

Carcinoma, Ovarian Epithelial

NCT06161025 2026-01-12

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2/3 Recruiting

860 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07189455 2026-01-05

Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer

420 enrolled

Small Cell Lung Carcinoma

NCT06855069 2025-12-17

HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

468 enrolled

Ovarian Neoplasms

NCT05874401 2025-09-04

Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan

Phase 4 Recruiting

302 enrolled

Small Cell Lung Carcinoma

NCT06954246 2025-06-18

A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

450 enrolled

Small Cell Lung Carcinoma

NCT06612151 2025-02-11

A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer

438 enrolled

Small Cell Lung Carcinoma

NCT06616532 2024-12-19

PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer

404 enrolled

SCLC

NCT06496048 2024-12-12

Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC

180 enrolled

Small Cell Lung Carcinoma

NCT06498479 2024-10-16

ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer

460 enrolled

Small Cell Lung Carcinoma

NCT06394492 2024-08-09

SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

440 enrolled

Ovarian Neoplasms

NCT06128837 2024-03-15

Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer

686 enrolled